You have 9 free searches left this month | for more free features.

il-2

Showing 1 - 25 of 60

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

NSCLC, Carcinoma Breast Trial in Suzhou (Vinorelbine, Radiotherapy, PD-1/PD-L1 inhibitor)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma Breast
  • Suzhou, China
    Second Affiliated Hospital of Soochow University
Oct 29, 2022

Colorectal Cancer, Hematologic Malignancy, Rectum Cancer Trial in Cleveland (Vactosertib, Fludarabine Phosphate,

Recruiting
  • Colorectal Cancer
  • +11 more
  • Cleveland, Ohio
    University Hospitals Cleveland Medical Center, Case Comprehensiv
Jan 18, 2023

Ovarian Cancer, Fallopian Tube Adenocarcinoma, Primary Peritoneal Cavity Cancer Trial in Minneapolis (IP FT516, Enoblituzumab,

Completed
  • Ovarian Cancer
  • +2 more
  • IP FT516
  • +2 more
  • Minneapolis, Minnesota
    University of Minnesota, Masonic Cancer Center
Apr 12, 2022

Advanced Refractory Solid Tumors Trial in China (Hypofractionated radiotherapy, PD-1 inhibitor, GM-CSF)

Recruiting
  • Advanced Refractory Solid Tumors
  • Hypofractionated radiotherapy
  • +3 more
  • Beijing, China
  • +15 more
Aug 8, 2022

Advanced Breast Cancer, Advanced Lung Cancer Trial (Tumor-infiltrating lymphocytes, IL-2)

Not yet recruiting
  • Advanced Breast Cancer
  • Advanced Lung Cancer
  • Tumor-infiltrating lymphocytes
  • IL-2
  • (no location specified)
Oct 26, 2023

Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer Trial in Huntersville (FT536, Cyclophosphamide, Fludarabine)

Recruiting
  • Non Small Cell Lung Cancer
  • +6 more
  • Scottsdale, Arizona
  • +4 more
Dec 27, 2022

Amyotrophic Lateral Sclerosis Trial in Beijing (IL-2)

Recruiting
  • Amyotrophic Lateral Sclerosis
  • IL-2
  • Beijing, Beijing, China
    Peking University Third Hospital
Aug 11, 2021

Purpura, Schoenlein-Henoch Trial in Changchun (IL-2)

Completed
  • Purpura, Schoenlein-Henoch
  • IL-2
  • Changchun, Changchun/JiLin, China
    Sirui Yang
Aug 16, 2022

Solid Tumor Trial (Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide Capsules)

Not yet recruiting
  • Solid Tumor
  • Tumor Infiltrating Lymphocytes
  • +3 more
  • (no location specified)
Dec 11, 2022

Solid Tumors Trial (TCR-T cells, Fludarabine, Cyclophosphamide Capsules)

Not yet recruiting
  • Solid Tumors
  • TCR-T cells
  • +4 more
  • (no location specified)
Dec 12, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in United States (IOV-2001, Low dose IL-2, High dose IL-2)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • IOV-2001
  • +3 more
  • Tampa, Florida
  • +5 more
Jan 31, 2022

Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, Relapsed, Adult Trial in Nijmegen (UCB-NK cells, IL-2)

Recruiting
  • Acute Myeloid Leukemia Refractory
  • Acute Myeloid Leukemia, Relapsed, Adult
  • UCB-NK cells
  • IL-2
  • Nijmegen, Netherlands
    Radboud University Medical Center
Nov 10, 2021

Metastatic Clear Cell Renal Cell Carcinoma Trial in Dallas (IL-2, Stereotactic Ablative Body Radiation Therapy)

Completed
  • Metastatic Clear Cell Renal Cell Carcinoma
  • IL-2
  • Stereotactic Ablative Body Radiation Therapy
  • Dallas, Texas
    University of Texas Southwestern Medical Center
Jul 28, 2021

Advanced Solid Tumors Trial in Chongqing (TC-N201 cells, IL-2, Fludarabine)

Recruiting
  • Advanced Solid Tumors
  • TC-N201 cells
  • +4 more
  • Chongqing, China
    TCRCure Biopharma Ltd.
May 25, 2023

Systemic Lupus Erythematosus Trial in Changchun (IL-2)

Completed
  • Systemic Lupus Erythematosus
  • IL-2
  • Changchun, Changchun/Jilin, China
    Sirui Yang
Aug 16, 2022

Amyotrophic Lateral Sclerosis Trial in France, United Kingdom (Riluzole, IL-2, 5% glucose water solution)

Completed
  • Amyotrophic Lateral Sclerosis
  • Lille, France
  • +16 more
Apr 1, 2022

Cervical Carcinoma Trial in Chongqing (TC-E202 cells, IL-2, Fludarabine)

Recruiting
  • Cervical Carcinoma
  • TC-E202 cells
  • +3 more
  • Chongqing, Chongqing, China
    Xiaochun Cheng
Oct 20, 2022

Solid Tumor, Adult Trial in Minneapolis, Hackensack, Houston (FT516, Avelumab, Cyclophosphamide)

Completed
  • Solid Tumor, Adult
  • Minneapolis, Minnesota
  • +2 more
Jan 27, 2023

R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma Trial (CNTY-101, IL-2,

Recruiting
  • R/R CD19-Positive B-Cell Malignancies
  • +2 more
  • CNTY-101
  • +2 more
  • Detroit, Michigan
  • +1 more
Dec 21, 2022

IL-2 "SELECT" Tissue Collection Protocol in Advanced Melanoma

Completed
  • Malignant Melanoma
  • IL-2
  • Boston, Massachusetts
    Beth Israel Deaconess Medical Center
Jan 13, 2021

Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia Trial in United States (FT819,

Recruiting
  • Lymphoma, B-Cell
  • +2 more
  • Birmingham, Alabama
  • +7 more
Jul 28, 2022

Leukemia, Acute Myeloid, Leukemia, Acute Lymphoblastic Trial in Minsk (Expanded Haploidentical Natural Killer cells, IL-2)

Completed
  • Leukemia, Acute Myeloid
  • Leukemia, Acute Lymphoblastic
  • Expanded Haploidentical Natural Killer cells
  • IL-2
  • Minsk, Minsk Region, Belarus
    Belarussian Research Center for Pediatric Oncology, Hematology a
Feb 28, 2022

Amputation, Traumatic, Amputation;Traumatic;Old, Face Injury Trial in Boston (IL-2)

Terminated
  • Amputation, Traumatic
  • +4 more
  • IL-2
  • Boston, Massachusetts
    Brigham and Women's Hospital
Jul 22, 2021

Advanced Solid Tumors, Lymphoma, Gastric Cancer Trial in United States (FT500, Nivolumab, Pembrolizumab)

Completed
  • Advanced Solid Tumors
  • +17 more
  • San Diego, California
  • +3 more
Jan 27, 2023

Carcinoma, Renal Cell Trial in Houston (TroVax, IL-2)

Completed
  • Carcinoma, Renal Cell
  • TroVax
  • IL-2
  • Houston, Texas
    The Methodist Hospital
Oct 9, 2020